Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics

Glaukos reported Q3 2026 revenue of $211.03 million, up 58% year-over-year and beating consensus estimates by 25%. EPS came in at $0.47 versus expectations of -$0.12, representing a 492% surprise. Strong performance was driven by U.S. Glaucoma revenue (+72.4%) and exceptional Corneal Health revenue growth (+172.3% in U.S., +153.4% overall). The stock has a Zacks Rank #2 (Buy) rating.